Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Dr Kanmin Xue has won the Ruskell Medal from the Worshipful Company of Spectacle Makers

Kanmin xue medal © WCSM/Mark Witter Photography

Kanmin Xue from our Clinical Ophthalmology Research Group won the award for a publication in Nature Medicine: Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia.

This paper provides the complete results of the world's first phase I/II study of retinal gene therapy for choroideremia, an important inherited cause of blindness. By demonstrating sustained preservation or improvement in visual acuity in the treated eyes over 2 to 5 years, the results led to the largest international multi-centre phase III trial of gene therapy to date, and helped to establish the protocols for evaluating changes in visual function and retinal anatomy in future retinal gene therapy trials. 

The medal was presented at a ceremony at the Worshipful Society of Apothecaries in London by The Master & Professor John Marshall (pictured with Kanmin above).

Kanmin Xue returns to our Department in January 2020 on a Wellcome Trust Clinical Research Development Fellowship and will set up his own research group.